1%3A19-cv-00626 - Bausch Health Irelandltd et al. v. Lupin Pharmaceuticals Inc et al.

Detail

Case Number

1:19-cv-00626

Current Status

closed

Cause of Action

Infringement

Related Case(s)

N/A

Court

Delaware District Court

Plaintiff(s)

Bausch Health Irelandltd

Norgine BV

Salix Pharmaceuticals Inc

Operating Company

Defendant(s)

Lupin Pharmaceuticals Inc

Lupin Ltd

Lupin Atlantis Holdings SA

Judge

Colm F. Connolly

Filing Date

2019-04-03

Termination Date

2019-08-05

Not a member? Sign up for free!
Dockets
Text
CIVIL DOCKET
UPDATED CIVIL DOCKET
No Summons Issued. (nmg) (Entered: 04/04/2019)
COMPLAINT for PATENT INFRINGEMENT filed against Lupin Atlantis Holdings SA, Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2610661.) - filed by Bausch Health Ireland Limited, Salix Pharmaceuticals, Inc., Norgine B.V.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Civil Cover Sheet)(nmg) (Entered: 04/04/2019)
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,999,313 B2 ;9,326,969 B2 ;9,592,252 B2 ;9,707,297 B2 ;10,016,504 B2. (Attachments: # 1 Notice)(fms) (Entered: 08/20/2019)
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) (Entered: 04/04/2019)
Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 2/19/2019. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 8/19/2021. (nmg) (Entered: 04/04/2019)
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,999,313 B2 ;9,326,969 B2 ;9,592,252 B2 ;9,707,297 B2 ;10,016,504 B2. (nmg) (Entered: 04/04/2019)
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bausch Health Companies Inc. for Bausch Health Ireland Limited, Salix Pharmaceuticals, Inc. filed by Bausch Health Ireland Limited, Salix Pharmaceuticals, Inc.. (nmg) (Entered: 04/04/2019)
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Norgine Europe B.V. for Norgine B.V. filed by Norgine B.V.. (nmg) (Entered: 04/04/2019)
STIPULATION TO EXTEND TIME for the Defendants Lupin Ltd., Lupin Atlantis Holdings SA, Lupin Inc. and Lupin Pharmaceuticals, Inc. to answer, move or otherwise respond to the Complaint to August 21, 2019 - filed by Lupin Atlantis Holdings SA, Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Phillips, John) (Entered: 07/22/2019)
NOTICE of Voluntary Dismissal by Bausch Health Ireland Limited, Norgine B.V., Salix Pharmaceuticals, Inc. as to Defendants Lupin LTD., Lupin Atlantis Holdings SA, Lupin Inc., and Lupin Pharmaceuticals, Inc. (Viceconte, Christopher) (Entered: 08/05/2019)
Timeline
filed_date
closed_date
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2020
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2021
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2022
Feb
Mar
Patents In Case

Not a member? Sign up for free!